Nio’s Stock Rises 30% As More Affordable Electric Vehicles Introduced
The stock of Chinese electric vehicle (EV) maker Nio (NIO) is surging after the company unveiled more affordable models that are likely to appeal to consumers and drive future sales.
Nio’s stock that trades in New York is up 5% in premarket action on Aug. 25 after a 14% gain on Aug. 22. In the last five trading sessions, the company’s share price has risen nearly 30%.
The rally comes after Nio unveiled its latest electric vehicle, the ES8 SUV, on Aug. 21. The model is priced at the equivalent of $43,000 U.S., making it a more affordable option for people.
Additionally, Nio’s monthly subscription plan allows vehicle owners to swap out depleted batteries for fresh ones, eliminating the need for a home charging system and lowering upfront costs.
Deliveries of the more affordable ES8 SUV are set to begin this September and are expected to give the company’s sales a boost heading into year end.
Nio’s more affordable electric vehicles are being introduced at a time of rising competition and pressure in China’s electric vehicle sector.
Until now, Nio has targeted the high-end vehicle market but is facing growing pressure from competitors that are rolling out electric vehicles with lower prices.
Nio recently launched two cheaper brands, Onvo, which targets the mass market, and Firefly, which caters to young urban consumers, in an effort to further drive sales.
NIO stock is now up 39% on the year and trading at $6.34 U.S. per share on the New York Stock Exchange (NYSE).
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


